biostudies-literatureAlden SLNIMHD NIH HHSNCI NIH HHS1312-1317https://www.ebi.ac.uk/biostudies/studies/S-EPMC10356567biostudies-literatureUnknown3(7)Combination anti-PD-(L)1/CTLA-4 blockade is approved in patients with hepatocellular carcinoma (HCC) in the first-line setting or after sorafenib, but whether this treatment has efficacy after prior anti-PD-(L)1 therapy is unknown. We performed a multicenter retrospective review of patients with advanced HCC treated with ipilimumab plus nivolumab after prior anti-PD-(L)1 therapy, excluding patients with prior anti-CTLA-4 treatment. Of the 32 patients who met our inclusion criteria, prior anti-PD-(L)1 regimens included atezolizumab plus bevacizumab (50%, <i>n</i> = 16), other anti-VEGF plus anti-PD-(L)1 combinations (31%, <i>n</i> = 10), and anti-PD-(L)1 monotherapy (19%, <i>n</i> = 6). The median number of prior systemic therapies was 2 (range, 1-8). The objective response rate with ipilimCancer research communicationsSalvage Ipilimumab plus Nivolumab after Anti-PD-1/PD-L1 Therapy in Advanced Hepatocellular Carcinoma.PMC10356567P30 CA006973U01 CA212007P50 CA062924R01 CA256977R01 MD012565R01 CA265009Kao CAlden SLGriffith PHo WJShu DSingal AGHsiehchen DNoonan ABaretti MLim MYarchoan MKamel IfalseSalvage Ipilimumab plus Nivolumab after Anti-PD-1/PD-L1 Therapy in Advanced Hepatocellular Carcinoma.Combination anti-PD-(L)1/CTLA-4 blockade is approved in patients with hepatocellular carcinoma (HCC) in the first-line setting or after sorafenib, but whether this treatment has efficacy after prior anti-PD-(L)1 therapy is unknown. We performed a multicenter retrospective review of patients with advanced HCC treated with ipilimumab plus nivolumab after prior anti-PD-(L)1 therapy, excluding patients with prior anti-CTLA-4 treatment. Of the 32 patients who met our inclusion criteria, prior anti-PD-(L)1 regimens included atezolizumab plus bevacizumab (50%, <i>n</i> = 16), other anti-VEGF plus anti-PD-(L)1 combinations (31%, <i>n</i> = 10), and anti-PD-(L)1 monotherapy (19%, <i>n</i> = 6). The median number of prior systemic therapies was 2 (range, 1-8). The objective response rate with ipilim2023-01-01T00:00:00Z2023 Jul2025-04-05T14:52:18.911Z2025-04-05T14:52:18.911ZS-EPMC103565673748420010.1158/2767-9764.CRC-23-0072